-
Je něco špatně v tomto záznamu ?
Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy
M Stiborova, E Frei, VM Arlt, HH Schmeiser
Jazyk angličtina Země Nizozemsko
Typ dokumentu přehledy
- MeSH
- balkánská nefropatie metabolismus patologie MeSH
- biotransformace MeSH
- chemické modely MeSH
- cytochrom P-450 CYP1A2 chemie metabolismus MeSH
- financování organizované MeSH
- karcinogeny chemie metabolismus MeSH
- kyseliny aristolochové chemie metabolismus MeSH
- lidé MeSH
- molekulární struktura MeSH
- rizikové faktory MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- přehledy MeSH
Aristolochic acid (AA), a naturally occurring nephrotoxin and carcinogen, is associated with tumor development in patients suffering from Chinese herbs nephropathy (now termed aristolochic acid nephropathy, AAN) and may also be a cause for the development of a similar type of nephropathy, the Balkan endemic nephropathy (BEN). Major DNA adducts [7-(deoxyadenosin-N6-yl)-aristolactam and 7-(deoxyguanosin-N2-yl)aristolactam] formed from AA after reductive metabolic activation were found in renal tissues of patients with both diseases. Understanding which human enzymes are involved in AA activation and/or detoxication is important in the assessment of an individual's susceptibility to this plant carcinogen. This paper reviews major hepatic and renal enzymes responsible for AA-DNA adduct formation in humans. Phase I biotransformation enzymes play a crucial role in the metabolic activation of AA to species forming DNA adducts, while a role of phase II enzymes in this process is questionable. Most of the activation of AA in human hepatic microsomes is mediated by cytochrome P450 (CYP) 1A2 and, to a lower extent, by CYP1A1; NADPH:CYP reductase plays a minor role. In human renal microsomes NADPH:CYP reductase is more effective in AA activation. Prostaglandin H synthase (cyclooxygenase, COX) is another enzyme activating AA in human renal microsomes. Among the cytosolic reductases, NAD(P)H:quinone oxidoreductase (NQO1) is the most efficient in the activation of AA in human liver and kidney. Studies with purified enzymes confirmed the importance of CYPs, NADPH:CYP reductase, COX and NQO1 in the AA activation. The orientation of AA in the active sites of human CYP1A1, -1A2 and NQO1 was predicted from molecular modeling and explains the strong reductive potential of these enzymes for AA detected experimentally. We hypothesized that inter-individual variations in expressions and activities of enzymes activating AA may be one of the causes responsible for the different susceptibilities to this carcinogen reflected in the development of AA-induced nephropathies and associated urothelial cancer.
Citace poskytuje Crossref.org
- 000
- 03712naa 2200409 a 4500
- 001
- bmc11003176
- 003
- CZ-PrNML
- 005
- 20111210202232.0
- 008
- 110225s2008 ne e eng||
- 009
- AR
- 024 __
- $a 10.1016/j.mrrev.2007.07.003 $2 doi
- 035 __
- $a (PubMed)17851120
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Stiborová, Marie, $d 1950-2020 $7 jo2005259907
- 245 10
- $a Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy / $c M Stiborova, E Frei, VM Arlt, HH Schmeiser
- 314 __
- $a Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic. stiborov@natur.cuni.cz
- 520 9_
- $a Aristolochic acid (AA), a naturally occurring nephrotoxin and carcinogen, is associated with tumor development in patients suffering from Chinese herbs nephropathy (now termed aristolochic acid nephropathy, AAN) and may also be a cause for the development of a similar type of nephropathy, the Balkan endemic nephropathy (BEN). Major DNA adducts [7-(deoxyadenosin-N6-yl)-aristolactam and 7-(deoxyguanosin-N2-yl)aristolactam] formed from AA after reductive metabolic activation were found in renal tissues of patients with both diseases. Understanding which human enzymes are involved in AA activation and/or detoxication is important in the assessment of an individual's susceptibility to this plant carcinogen. This paper reviews major hepatic and renal enzymes responsible for AA-DNA adduct formation in humans. Phase I biotransformation enzymes play a crucial role in the metabolic activation of AA to species forming DNA adducts, while a role of phase II enzymes in this process is questionable. Most of the activation of AA in human hepatic microsomes is mediated by cytochrome P450 (CYP) 1A2 and, to a lower extent, by CYP1A1; NADPH:CYP reductase plays a minor role. In human renal microsomes NADPH:CYP reductase is more effective in AA activation. Prostaglandin H synthase (cyclooxygenase, COX) is another enzyme activating AA in human renal microsomes. Among the cytosolic reductases, NAD(P)H:quinone oxidoreductase (NQO1) is the most efficient in the activation of AA in human liver and kidney. Studies with purified enzymes confirmed the importance of CYPs, NADPH:CYP reductase, COX and NQO1 in the AA activation. The orientation of AA in the active sites of human CYP1A1, -1A2 and NQO1 was predicted from molecular modeling and explains the strong reductive potential of these enzymes for AA detected experimentally. We hypothesized that inter-individual variations in expressions and activities of enzymes activating AA may be one of the causes responsible for the different susceptibilities to this carcinogen reflected in the development of AA-induced nephropathies and associated urothelial cancer.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kyseliny aristolochové $x chemie $x metabolismus $7 D034341
- 650 _2
- $a balkánská nefropatie $x metabolismus $x patologie $7 D001449
- 650 _2
- $a biotransformace $7 D001711
- 650 _2
- $a karcinogeny $x chemie $x metabolismus $7 D002273
- 650 _2
- $a cytochrom P-450 CYP1A2 $x chemie $x metabolismus $7 D019388
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chemické modely $7 D008956
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a financování organizované $7 D005381
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Frei, Eva. $7 _AN036392
- 700 1_
- $a Arlt, Volker M. $7 xx0074763
- 700 1_
- $a Schmeiser, H. H.
- 773 0_
- $t Mutation Research $w MED00003430 $g Roč. 658, č. 1-2 (2008), s. 55-67 $x 0027-5107
- 910 __
- $a ABA008 $b B 1575 $y 7
- 990 __
- $a 20110413115230 $b ABA008
- 991 __
- $a 20111128104206 $b ABA008
- 999 __
- $a ok $b bmc $g 830532 $s 695169
- BAS __
- $a 3
- BMC __
- $a 2008 $b 658 $c 1-2 $d 55-67 $i 0027-5107 $m Mutation research $n Mutat Res $x MED00003430
- LZP __
- $a 2011-2B/ipme